Rondo Therapeutics begins dosing in Phase I/Ib trial for solid tumours
Rondo Therapeutics has initiated dosing in its Phase I/Ib clinical trial of first-in-class bispecific antibody, RNDO-564, targeting Cluster of Differentiation…
All articles by Salong Debbarma
Salong Debbarma
-
-
FDA clears VectorY’s PIONEER-ALS Phase I/II trial for ALS
VectorY Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application…
-
PolarityBio concludes SkinTE’s Phase III trial for diabetic foot ulcers
PolarityBio has completed the COVER DFUS II pivotal Phase III clinical trial of its autologous heterogeneous skin construct product, SkinTE,…
-
Vandria announces topline results from Phase I trial of VNA-318
Vandria has announced positive top line data from its first-in-human Phase I clinical trial evaluating VNA-318, a central nervous system…
-
AbbVie reports Phase III study results of atogepant
AbbVie has reported primary data from the ECLIPSE Phase III study, assessing the tolerability, safety and efficacy of Aquipta (atogepant)…
-
IDEAYA receives FDA approval to begin IDE034 clinical trial
IDEAYA has received the US Food and Drug Administration (FDA) clearance of an investigational new drug (IND) application to begin…
-
Imugene announces Phase Ib azer-cel efficacy data
Imugene has announced further positive efficacy data from its ongoing Phase Ib azer-cel (azercabtagene zapreleucel) trial in relapsed/refractory diffuse large…
-
Zuellig Pharma launches clinical trial facility in South Korea
Zuellig Pharma has opened its new innovation centre in South Korea for supporting both domestic and worldwide clinical research needs.…
-
InnoCare doses first patient in Phase II trial of soficitinib
InnoCare has dosed the first patient in a global Phase II trial of its selective and potent tyrosine kinase 2…
-
Gan & Lee begins Phase III GLP-1 RA clinical trial in China
Gan & Lee Pharmaceuticals has initiated the Phase III GRADUAL-3 clinical trial of once-monthly glucagon-like peptide-1 receptor agonist (GLP-1 RA)…